Inhibitory effects of dobutamine on human gastric adenocarcinoma

World Journal of Gastroenterology

Volumn 20, Issue 45, 2014, Pages 17092-17099

  Zheng, Hui Xia ^a   Wu, Li Na ^a   Xiao, Hong ^a   Du, Qian ^a   Liang, Jian Fang ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Dobutamine; Gastric adenocarcinoma cells; Hippo pathway; Human gastric adenocarcinoma cell line SGC 7901; Therapy; Yes Associated protein

Indexed keywords

CISPLATIN; DOBUTAMINE; MATRIGEL; TUMOR PROTEIN; UNCLASSIFIED DRUG; YAP PROTEIN; ANTINEOPLASTIC AGENT; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CYTOSOL; DRUG EFFECT; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GASTRIC CANCER CELL LINE; HUMAN; IMMUNOCYTOCHEMISTRY; MTT ASSAY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STOMACH ADENOCARCINOMA; TUMOR INVASION; WESTERN BLOTTING; WOUND HEALING; ADENOCARCINOMA; CELL MOTION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; STOMACH TUMOR; TIME; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DOBUTAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; NEOPLASM INVASIVENESS; PHOSPHOPROTEINS; PHOSPHORYLATION; STOMACH NEOPLASMS; TIME FACTORS;

EID: 84917706338     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i45.17092     Document Type: Article

References (24)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29 [PMID: 22237781 DOI: 10.3322/caac.20138]
2. Ruffolo RR. The pharmacology of dobutamine. Am J Med Sci 1987; 294: 244-248 [PMID: 3310640 DOI: 10.1097/0000044 1-198710000-00005]
3. Vallet B, Dupuis B, Chopin C. [Dobutamine: mechanisms of action and use in acute cardiovascular pathology]. Ann Cardiol Angeiol (Paris) 1991; 40: 397-402 [PMID: 1859148]
4. Robbers-Visser D, Luijnenburg SE, van den Berg J, Roos-Hesselink JW, Strengers JL, Kapusta L, Moelker A, Helbing WA. Safety and observer variability of cardiac magnetic resonance imaging combined with low-dose dobutamine stresstesting in patients with complex congenital heart disease. Int J Cardiol 2011; 147: 214-218 [PMID: 19740557 DOI: 10.1016/ j.ijcard.2009.08.024]
5. Bao Y, Nakagawa K, Yang Z, Ikeda M, Withanage K, Ishigami-Yuasa M, Okuno Y, Hata S, Nishina H, Hata Y. A cellbased assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription. J Biochem 2011; 150: 199-208 [PMID: 21586534 DOI: 10.1093/jb/mvr063]
6. Edgar BA. From cell structure to transcription: Hippo forges a new path. Cell 2006; 124: 267-273 [PMID: 16439203 DOI: 10.1016/j.cell.2006.01.005]
7. Pan D. Hippo signaling in organ size control. Genes Dev 2007; 21: 886-897 [PMID: 17437995 DOI: 10.1101/gad.1536007]
8. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA, Anders RA. Expression of Yes-Associated protein in common solid tumors. Hum Pathol 2008; 39: 1582-1589 [PMID: 18703216 DOI: 10.1016/j.humpath.2008.04.012]
9. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, Mu D, Lucito R, Powers S, Lowe SW. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006; 125: 1253-1267 [PMID: 16814713 DOI: 10.1016/j.cell.2006.05.030]
10. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS, Haber DA. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 2006; 103: 12405-12410 [PMID: 16894141 DOI: 10.1073/pnas.0605579103]
11. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer 2006; 6: 753-763 [PMID: 16990853]
12. Castle PE, Dockter J, Giachetti C, Garcia FA, McCormick MK, Mitchell AL, Holladay EB, Kolk DP. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res 2007; 13: 2599-2605 [PMID: 17473189 DOI: 10.1002/jmv.20062]
13. Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J Med Virol 2004; 73: 65-70 [PMID: 15042650]
14. Da CL, Xin Y, Zhao J, Luo XD. Significance and relationship between Yes-Associated protein and survivin expression in gastric carcinoma and precancerous lesions. World J Gastroenterol 2009; 15: 4055-4061 [PMID: 19705503 DOI: 10.3748/wjg.15.4055]
15. Yuan M, Tomlinson V, Lara R, Holliday D, Chelala C, Harada T, Gangeswaran R, Manson-Bishop C, Smith P, Danovi SA, Pardo O, Crook T, Mein CA, Lemoine NR, Jones LJ, Basu S. Yes-Associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 2008; 15: 1752-1759 [PMID: 18617895 DOI: 10.1038/cdd.2008.108]
16. Molden T, Kraus I, Karlsen F, Skomedal H, Hagmar B. Human papillomavirus E6/E7 mRNA expression in women younger than 30 years of age. Gynecol Oncol 2006; 100: 95-100 [PMID: 16153696 DOI: 10.1016/j.ygyno.2005.07.108]
17. Zeng Q, Hong W. The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell 2008; 13: 188-192 [PMID: 18328423 DOI: 10.1016/j.ccr.2008.02.011]
18. Oka T, Remue E, Meerschaert K, Vanloo B, Boucherie C, Gfeller D, Bader GD, Sidhu SS, Vandekerckhove J, Gettemans J, Sudol M. Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. Biochem J 2010; 432: 461-472 [PMID: 20868367 DOI: 10.1042/BJ20100870]
19. Zhao B, Lei QY, Guan KL. The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol 2008; 20: 638-646 [PMID: 18955139 DOI: 10.1016/j.ceb.2008.10.001]
20. Zhang H, Wu S, Xing D. Inhibition of Aβ(25-35)-induced cell apoptosis by low-power-laser-irradiation (LPLI) through promoting Akt-dependent YAP cytoplasmic translocation. Cell Signal 2012; 24: 224-232 [PMID: 21945154 DOI: 10.1016/ j.cellsig.2011.09.004]
21. Zhou Z, Zhu JS, Xu ZP. RNA interference mediated YAP gene silencing inhibits invasion and metastasis of human gastric cancer cell line SGC-7901. Hepatogastroenterology 2011; 58: 2156-2161 [PMID: 22024089 DOI: 10.5754/hge11234]
22. Lapi E, Di Agostino S, Donzelli S, Gal H, Domany E, Rechavi G, Pandolfi PP, Givol D, Strano S, Lu X, Blandino G. PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell 2008; 32: 803-814 [PMID: 19111660 DOI: 10.1016/j.molcel.2008.11.019]
23. Liu FS. Mechanisms of chemotherapeutic drug resistance in cancer therapy-A quick review. Taiwan J Obstet Gynecol 2009; 48: 239-244 [PMID: 19797012 DOI: 10.1016/S1028-4559(09)60296-5]
24. Cho HJ, Baek KE, Nam IK, Park SM, Kim IK, Park SH, Im MJ, Ryu KJ, Yoo JM, Hong SC, Kim JW, Lee CW, Yoo J. PLCγ is required for RhoGDI2-mediated cisplatin resistance in gastric cancer. Biochem Biophys Res Commun 2011; 414: 575-580 [PMID: 21986528 DOI: 10.1016/j.bbrc.2011.09.121]